Welcome to our dedicated page for PALATIN TECHNOLOGIES SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PALATIN TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PALATIN TECHNOLOGIES's regulatory disclosures and financial reporting.
Palatin Technologies director Arlene Morris received a grant of stock options covering 2,400 shares of common stock with an exercise price of $7.70 per share. The options vest 50% on August 3, 2027 and 50% on August 3, 2028, and expire on August 3, 2037. After this award, she directly holds 3,497 stock options. The grant was approved by the Compensation Committee under Palatin’s 2011 Stock Incentive Plan and is reported under a Rule 10b5-1 trading arrangement.
DUNTON ALAN W reported acquisition or exercise transactions in this Form 4 filing.
PALATIN TECHNOLOGIES INC director Alan W. Dunton was granted 2,200 stock options under the 2011 Stock Incentive Plan, exercisable at $7.70 per share and granted on August 3, 2026. The options vest 50% on August 3, 2027 and 50% on August 3, 2028, and expire on August 3, 2037.
After this grant, Dunton holds 25,769 derivative securities tied to Palatin common stock. The grant is affirmed as made under a Rule 10b5-1 trading plan.
PALATIN TECHNOLOGIES INC director John K A Prendergast reported receiving a stock option covering 2,900 shares of common stock at an exercise price of $7.70 per share under the 2011 Stock Incentive Plan. The option vests 50% on August 3, 2027 and 50% on August 3, 2028, and expires on August 3, 2037, leaving him with stock options over 26,921 shares in total.
Palatin Technologies, Inc. held its annual meeting of stockholders on July 28, 2026, where four proposals were presented: election of directors, ratification of the independent registered public accounting firm for the fiscal year ending June 30, 2026, an amendment to the 2011 Stock Incentive Plan to increase shares available for equity awards by 260,000 shares, and an advisory vote on executive compensation for the fiscal year ended June 30, 2025.
As of the June 22, 2026 record date, there were 1,842,625 votes entitled to be cast, including 1,779,275 common shares, 4,030 shares of Series A Preferred Stock (1,534 votes), and 3,400 shares of Series D Preferred Stock (61,816 votes). A total of 1,000,506 votes, or 54.3% of votes entitled, were present in person or by proxy. Director nominees received between 337,172 and 654,056 votes for, with 319,687 broker non-votes each. The auditor ratification proposal received 982,584 for, 15,833 against, and 2,089 abstentions; the stock plan amendment received 650,452 for, 28,736 against, 1,630 abstentions, and 319,687 broker non-votes; and the say-on-pay proposal received 649,559 for, 28,732 against, 2,527 abstentions, and 319,687 broker non-votes.
Palatin Technologies President and CEO Carl Spana reported three F-code transactions in common stock dated July 15, 2026. In total, 294 shares were withheld by the issuer at per-share values of $14.34, $11.72 and $11.77 to satisfy employee withholding taxes on recently vested stock grants.
Palatin Technologies Executive VP and CFO/COO Stephen T. Wills reported tax-withholding dispositions totaling 195 shares of common stock on July 15, 2026. The company withheld 94, 79 and 22 shares at per-share values of $14.34, $11.72 and $11.77 to satisfy employee withholding taxes on recently vested equity grants. After these transactions, Wills directly owned 63,792 common shares. The filing affirms these transactions under a Rule 10b5-1 trading plan.
Palatin Technologies is asking stockholders to approve four main items at its fully virtual annual meeting on July 28, 2026. Stockholders will vote on electing four directors, ratifying KPMG as auditor for the year ending June 30, 2026, amending the 2011 Stock Incentive Plan, and an advisory say-on-pay resolution.
The equity plan amendment would add 260,000 shares of common stock to the reserve, bringing total authorized under the plan to 406,000 shares, to continue granting stock options and restricted stock units to employees, directors, and consultants. As of the June 22, 2026 record date, there were 1,779,275 common shares outstanding, with additional voting power from Series A and Series D convertible preferred stock.
The proxy describes how to register, attend, and vote at the virtual-only meeting, details quorum and broker voting rules, and outlines board structure, committee responsibilities, director independence, and director compensation. It also discloses 2024–2025 audit and tax fees paid to KPMG and key terms of the amended equity plan, including minimum vesting periods, change-in-control treatment, overhang metrics, and clawback and detrimental-activity provisions.
Palatin Technologies, Inc. filed a Form 25 notifying the SEC and NYSE American LLC of the removal of its class of securities from listing and registration. The filing certifies compliance with the Exchange rules and 17 CFR 240.12d2-2 procedures. The Form is signed by the company CFO on May 28, 2026.
Palatin Technologies, Inc. plans to move its common stock listing from the NYSE American to the Nasdaq Capital Market. Trading on the NYSE American is expected to end on May 28, 2026, with Nasdaq trading beginning May 29, 2026, under the same symbol “PTN.”
The company develops melanocortin receptor–targeted therapies, including selective MC4R-based obesity programs for rare disorders such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. A once-weekly injectable MC4R agonist is targeted for an IND submission in the fourth quarter of 2026, and an oral MC4R agonist candidate is targeted for IND submission in the first half of 2027.
Palatin Technologies Inc reports that Logos Global and related reporting persons each beneficially own 182,162 shares of Common Stock, representing 9.9% of the class.
The filing states the percentage calculation references 1,779,275 shares outstanding as of May 12, 2026 and discloses warrants to acquire 224,000 shares plus an alternate beneficially owned count of 137,992 shares used in the percentage calculation. The reporting persons say the securities are held on behalf of Logos Opportunities Fund IV and that they disclaim group membership and broader beneficial ownership beyond their pecuniary interest.